Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01004380
Recruitment Status : Completed
First Posted : October 29, 2009
Last Update Posted : July 17, 2014
Sponsor:
Information provided by (Responsible Party):
Morphotek

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : August 2012
Actual Study Completion Date : October 2012